Silence Therapeutics Plc American Depository Share - SLN STOCK NEWS

Silence Therapeutics has received Fast Track Designation from the FDA for SLN124, an siRNA targeting the TMPRSS6 gene, aimed at treating polycythemia vera (PV). This designation could accelerate the development and review process, enabling quicker patient access to treatments. SLN124 has shown proof of mechanism and tolerability in prior studies. The company also plans to initiate a phase 1/2 study this year and is evaluating SLN124 for other hematological diseases.

Silence Therapeutics plc (NASDAQ: SLN) announced pricing for an underwritten offering of 5,950,000 American Depositary Shares (ADSs) at $9.50 each, yielding approximately $56.5 million before expenses. The offering aims to fund clinical trials, including Phase 2 SLN360 for ASCVD and Phase 1/2 SLN124 for polycythemia vera. The offering is expected to close around August 16, 2022. Morgan Stanley and William Blair are joint book-running managers. Silence's focus is on RNA interference therapeutics targeting significant unmet medical needs.

Silence Therapeutics plc, a leader in siRNA therapeutics, announced its participation in the Jefferies Healthcare Conference on June 9, 2022, at 10:00 a.m. EDT / 2:00 p.m. GMT. The presentation will be accessible via a live webcast on the company’s website, with an archived replay available afterward. Silence is focused on RNA interference technology to develop treatments for diseases, with key products including SLN360 for cardiovascular risk and SLN124 for hematological disorders. The company collaborates with AstraZeneca and others.

Silence Therapeutics plc (NASDAQ: SLN) announced its participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The on-demand presentation will be available on May 23 at 7:00 AM ET via the Silence website. Silence specializes in RNA interference (RNAi) therapeutics targeting significant unmet medical needs. Key candidates include SLN360 for cardiovascular risk reduction and SLN124 for hematological diseases. The Company collaborates with AstraZeneca and others to advance its innovative therapies.

Silence Therapeutics plc (NASDAQ: SLN) reported its Q1 2022 financial results, highlighting progress in its development pipeline. Key achievements include positive SLN360 data presented at ACC and FDA orphan drug designation for SLN124. Financially, the company generated £5.7 million in revenue, up from £3.1 million in Q1 2021, while net loss decreased to £7.7 million from £8.4 million. As of March 31, 2022, cash and equivalents totaled £59.3 million. The company anticipates further milestones, including durability data for SLN360 and topline results for SLN124, both expected in Q3 2022.

Silence Therapeutics plc (Nasdaq: SLN) announced a $2.0 million cash payment from Hansoh Pharmaceutical Group, following the achievement of a preclinical milestone in their collaboration established in October 2021. This deal involves developing siRNAs utilizing Silence’s mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to two targets outside China, while Hansoh holds rights in China. Silence also stands to gain up to $1.3 billion in additional milestones and royalties from Hansoh's net product sales.

Silence Therapeutics, listed on Nasdaq as SLN, announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. Eastern Time. The presentation will focus on the company's innovative siRNA therapeutics aimed at treating unmet medical needs, including cardiovascular risks and rare hematological diseases. A live webcast will be available on the company’s website, followed by a replay. Silence leverages its proprietary mRNAi GOLD™ platform and collaborates with major industry players.

Silence Therapeutics announced results from the phase 1 APOLLO trial of SLN360, an siRNA targeting lipoprotein(a) (Lp(a)), presented at the ACC.22 event in Washington, D.C. The trial demonstrated a reduction of Lp(a) levels by up to 98% in healthy adults with elevated Lp(a). Results were published in the Journal of the American Medical Association, enhancing the visibility of their groundbreaking therapy aimed at decreasing heart disease risk. SLN360 is designed to temporarily block the LPA gene, potentially lowering the risk of heart attacks and strokes.

SLN360 demonstrated a significant reduction in lipoprotein(a) (Lp(a)), a key genetic risk factor for heart disease, with reductions of up to 98% observed in the phase 1 APOLLO trial. Results showed that reductions of up to 81% persisted at 150 days. These findings, published in The Journal of the American Medical Association, support the further development of SLN360, which targets Lp(a) production. The study involved 32 adults and reported no serious safety concerns. Silence Therapeutics plans to advance SLN360 into phase 2 trials focused on patients with cardiovascular disease.